Serum S100B level may be correlated with carbon monoxide poisoning

2015 ◽  
Vol 27 (1) ◽  
pp. 69-75
Author(s):  
Hui Liu ◽  
Yu Zhang ◽  
Yan-Bo Ren ◽  
Jian Kang ◽  
Jing Xing ◽  
...  
2012 ◽  
Vol 50 (3) ◽  
pp. 183-188 ◽  
Author(s):  
Eunjung Park ◽  
Junghwan Ahn ◽  
Young-Gi Min ◽  
Yoon-Seok Jung ◽  
Kyuseok Kim ◽  
...  

2012 ◽  
Vol 30 (1) ◽  
pp. 222-225 ◽  
Author(s):  
Toshimitsu Ide ◽  
Yoshito Kamijo ◽  
Ayako Ide ◽  
Kuniko Yoshimura ◽  
Takashi Nishikawa ◽  
...  

Author(s):  
Haldun Akoglu ◽  
Arzu Denizbasi ◽  
Ozlem Guneysel ◽  
Ozge Ecmel Onur ◽  
Serkan Emre Eroglu ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Asuman Celikbilek ◽  
Mehmet Celikbilek ◽  
Seda Sabah ◽  
Nermin Tanık ◽  
Elif Borekci ◽  
...  

Objective. Recent studies have demonstrated that enteric glial cells (EGC) participate in the homeostasis of the gastrointestinal tract. This study investigated whether enteroglial markers, including S100B protein and glial fibrillary acidic protein (GFAP), can serve as noninvasive indicators of EGC activation and disease activity in UC patients.Methods. This clinical prospective study included 35 patients with UC and 40 age- and sex-matched controls. The diagnosis of UC was based on standard clinical, radiological, endoscopic, and histological criteria. Clinical disease activity was evaluated using the Modified Truelove-Witts Severity Index. Serum samples were analyzed for human GFAP and S100B using commercial enzyme-linked immunosorbent assay kits.Results. GFAP was not detected in the serum of either UC patients or controls (P>0.05). However, we found a significant (P<0.001) decrease in the serum S100B levels in the UC patients. No correlation between the serum S100B level and the disease activity or duration was observed (P>0.05). The serum S100B levels did not differ between UC patients with active disease (24 patients, 68.6%) or in remission (11 patients, 31.4%) (P>0.05).Conclusions. Ulcerative colitis patients had significantly lower serum S100B levels, while GFAP was of no diagnostic value in UC patients.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20042-e20042
Author(s):  
Igor Samoylenko ◽  
Tatiana Zabotina ◽  
Irina N. Mikhaylova ◽  
George Z. Chkadua ◽  
Olga V. Korotkova ◽  
...  

e20042 Background: The purpose of this sub study was to identify peripheral blood biomarkers associated with the therapeutic effect of immunotherapy with dendritic cell vaccine in patients with metastatic melanoma (MM). Methods: Patients (pts) with low disease burden achieved disease control after two cycles of chemo (cisplatine, vinbalstie, DTIC) were randomized dendritic cell vaccine (DC) or three cycles of chemo. Vaccination schedule consisted of 5 subcutaneous injections of dendritic cell (DC) vaccine (2×106 cells pulsed with autologous lysate) with 14 days intervals. S100B level, LDH level, and peripheral blood lymphocytes immune phenotype were assessed before treatment, after two cycles of chemo and after each vaccination cycle. Results: 104 pts were included in the study, 30 pts were randomized to DC arm, 29 pts were randomized to continue chemo. In pts with rapid disease progression baseline serum S100b level was significantly higher compared to patients with objective response or stable disease (0.874±1.15 mcg/L vs. 0.361±0.66 mcg/L, P=0.002). Similar results were found for baseline serum LDH level (559.8±469.7 U/L vs. 412.5±184.4 U/L, P=0.005) and serum S100b level after 2 cycles of chemo (0.688±0.855 mcg/L vs. 0.187±0,29 mcg/L, P<0.001). Contrary, baseline CD3+HLA-DR+ and CD4+CD25+ lymphocytes levels after 2 cycles of chemo were significantly higher in pts with disease control (11.9±8.9% vs. 8.9±5.3%, P=0.047 and 14.4±8.3% vs. 11.3±5.5%, P=0.036 respectively).In pts randomized to DC arm following markers were associated with long lasting objective response or stable disease course (>6 months): lower baseline S100b level (0.133±0.120 mcg/L vs. 0.445±0.406 mcg/L, P=0.014), lower S100b level after 2 cycles of chemo (0.105±0.095 mcg/L vs. 0.255±0.154 mcg/L, P=0.048), higher proportion of active CD8+lymphocytes prior to vaccination (74.7±3.6% vs. 51.7±14.2%, P=0.05); and more prominent increase of NK-cells CD3-CD16+CD56+ from baseline (increase in 76.5%±41.12% vs. 4.5±28.8%, P=0.01). Conclusions: Biochemical and immunological markers may be helpful when selecting patients with metastatic melanoma for immunotherapy with dendritic cell vaccine.


2009 ◽  
Vol 27 (7) ◽  
pp. 838-842 ◽  
Author(s):  
Turker Yardan ◽  
Yunsur Cevik ◽  
Omer Donderici ◽  
Cemil Kavalci ◽  
Fatma Meric Yilmaz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document